The FibroScan mini 430 expanding access to the FibroScan technology. The most lightweight and portable option of the FibroScan family
Expand the reach of your
Using patented VCTE™ and CAP™ technologies, the FibroScan mini+ system is the latest and smallest addition to the FibroScan family of products.
Expanding innovation, the FibroScan mini+ offers mobility with the same experience and consistent results that you have come to expect from the FibroScan Compact systems.
Fibroscan mini+ ultra mobile design is ideal for multi-centers configuration and remote patients liver monitoring.
Fully compatible with FibroScan Gateway, allowing for improved patient management and efficiencies.
Touch screen data entry of 12.1 inches
Easy to transport – light weight: Approx 11lbs, Size: L=11″, x W=15.7″, x D= 3.7″
Plug in or Battery operated
Two probe connectors to easily switch between M+ and XL+ adult probes during the examination
Connectivity options: Multiple USB ports (export data, report to USB devices, exam report can be printed or exported on an external drive) to share information instantly
FibroScan® Gateway compatible
Available S+ probe for pediatric use
Indications for use
FibroScan Family of Products are indicated for noninvasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter).
The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.
Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.
Current media
Echosens Featured in OncologyTube
Scott Howell, DO, MPH & TM, CPE, Advisor to Echosens, was featured in OncologyTube interview: “Underlying Nonalcoholic Fatty Liver Disease is a Significant Factor for Breast Cancer Recurrence After Curative…
Read More
Comprehensive Economical Analysis Shows Screening Diabetic Patients for NAFLD is Cost Effective in the United States
The prevalence of non-alcoholic fatty liver disease (NAFLD) has reached epidemic levels. The most common liver disease, with a worldwide prevalence of 25%, NAFLD and its subtype, nonalcoholic steatohepatitis (NASH),…
Read More
Echosens Presents Research at 2020 AASLD Liver Meeting
November 13, 2020 08:03 AM Eastern Standard Time Documentation for Payers on Cost Effectiveness of FibroScan Screening for Detecting, Monitoring Fatty Liver Disease WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering…
Read More
Contact a representative
In North America there are over 1200+ FibroScan systems in operation & we’re growing!
